期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?
1
作者 Benoit Souchet Mickael Audrain +3 位作者 Baptiste Billoir Laurent Lecanu Satoru Tada Jérome Braudeau 《Neural Regeneration Research》 SCIE CAS CSCD 2018年第2期224-225,共2页
Alzheimer's disease (AD) is the most frequent cause of dementia in the western world. In clinical terms, AD is characterized by progres- sive cognitive decline that usually begins with memory impairment. As the dis... Alzheimer's disease (AD) is the most frequent cause of dementia in the western world. In clinical terms, AD is characterized by progres- sive cognitive decline that usually begins with memory impairment. As the disease progresses, AD inevitably affects all intellectual functions including executive functions, leading to complete dependence for basic activities of daily life and premature death. 展开更多
关键词 AD Is it time to rethink the Alzheimer’s disease drug development strategy by targeting its silent phase
下载PDF
Molecular targets for COVID-19 drug development:Enlightening Nigerians about the pandemic and future treatment 被引量:1
2
作者 Yusuf Muhammed 《Biosafety and Health》 2020年第4期210-216,共7页
There is little or no research initiated on enlightening Nigerians about the pathogenesis,targets for drug development and repositioning for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.Coronav... There is little or no research initiated on enlightening Nigerians about the pathogenesis,targets for drug development and repositioning for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.Coronavirus disease 2019(COVID-19)is a viral infection causing symptoms like dry cough,sore throat,nasal congestion,tiredness,fever,loss of taste,and smell etc.The disease was first reported in Wuhan,China,in December 2019.The infection is caused by SARS-CoV-2,which is the third introduction of a highly pathogenic coronavirus into the human population.Coronaviruses are viruses with a positive RNA envelope assigned toα,β,γ,andδgenera.Moreover,SARS-CoV-2 belongs to theβgenus.The four structural proteins ofβcoronavirus are membrane(M),envelope(E),spike(S),and nucleocapsid(N)protein,mediation of coronavirus host infection is established by spike(S)protein.Therefore,the search for drug development targets and repositioning of existing therapeutics is essential for fighting the present pandemic.It was reviewed that therapeutics targeting SARS-CoV-2 binding to ACE2 receptor,viral RNA synthesis and replication,3CLpro,RdRp,and helicase will play a crucial role in the development of treatment for SARS-CoV-2 infection.Furthermore,the RdRp and spike protein of SARS-CoV-2 are the most promising targets for drug development and repositioning and vaccine development.Remdesivir combination with chloroquine/hydroxychloroquine are promising drug repositioning for the treatment of COVID-19,and mRNA-1273 targeting spike protein is the promising vaccine.However,as patient management and drug repositioning are taking place,it is imperative to identify other promising targets used by SARS-CoV-2 to establish infection,to develop novel therapeutics. 展开更多
关键词 SARS-CoV-2 COVID-19 Molecular pathogenesis Acute respiratory disease drug development targets
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部